COMPANY PROFILE

POINT Biopharma

Explore full profile

Developing next-generation radioligand therapies for the treatment of cancer

Indianapolis, United StatesFounded 2019Biotech & Life Sciences

Valuation $1.33B Market cap · 2024

Revenue $14M Latest reported FY

EBITDA $127M Latest reported FY

About POINT Biopharma

POINT Biopharma is a cutting-edge radiopharmaceutical company focused on developing next-generation treatments for cancer. Operating in the precision oncology market, POINT Biopharma specializes in creating radiopharmaceuticals that deliver high energy particles directly to cancer cells, minimizing damage to surrounding healthy tissue. The company's primary clients include healthcare providers, oncologists, and cancer treatment centers. POINT Biopharma's business model revolves around the research, development, and commercialization of these advanced therapies, with revenue generated through clinical trials, partnerships, and eventual product sales. The company is currently enrolling patients in its Phase 3 SPLASH trial for metastatic castration-resistant prostate cancer, showcasing its commitment to advancing cancer treatment through rigorous clinical research.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2019
Headquarters: Indianapolis, United States
Listing: IPO 2020
Sector: Biotech & Life Sciences
Power Law: Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

UTUniversity of Toronto
MUMcMaster University

Talent

Book a demo to see the people

Team profiled 10 named & role-tagged

Founders /100 quality score

Key operators 1 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

2 countries with
team presence

🇺🇸 United States72.7%

🇨🇦 Canada27.3%

2 countries shown

Patents

Estimated portfolio value

$771k

7 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about POINT Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See POINT Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles